CN Stock MarketDetailed Quotes
300760 Shenzhen Mindray Bio-Medical Electronics
- 243.66
- -4.19-1.69%
Market Closed Jan 3 15:00 CST
295.42BMarket Cap23.85P/E (TTM)
249.13High243.07Low47.43KlotVolume247.86Open247.85Pre Close1.17BTurnover0.39%Turnover Ratio25.51P/E (Static)1.21BShares349.9552wk High8.42P/B295.42BFloat Cap219.0052wk Low297.42Limit Up1.21BShs Float482.50Historical High198.28Limit Down2.45%Amplitude34.06Historical Low7.21Dividend TTM246.16Avg Price19.37KlotAsk2.96%Div YieldTTM100Lot Size21.69KlotBid
Shenzhen Mindray Bio-Medical Electronics Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 7.99%29.48B | 11.12%20.53B | 12.06%9.37B | 15.04%34.93B | 17.20%27.3B | 20.32%18.48B | 20.47%8.36B | 20.17%30.37B | 20.13%23.3B | 20.17%15.36B |
| Operating revenue | 7.99%29.48B | 11.12%20.53B | 12.06%9.37B | 15.04%34.93B | 17.20%27.3B | 20.32%18.48B | 20.47%8.36B | 20.17%30.37B | 20.13%23.3B | 20.17%15.36B |
| Other operating revenue | ---- | 79.38%39.29M | ---- | 378.66%56.61M | ---- | 319.44%21.91M | ---- | 0.82%11.83M | ---- | 25.02%5.22M |
| Total operating cost | 7.97%17.87B | 8.20%12.39B | 8.99%6.07B | 10.92%21.99B | 14.62%16.55B | 19.74%11.45B | 20.36%5.57B | 18.95%19.83B | 19.16%14.44B | 19.24%9.56B |
| Operating cost | 5.84%10.36B | 9.00%6.93B | 13.50%3.19B | 8.59%11.82B | 17.68%9.79B | 15.40%6.36B | 16.00%2.81B | 23.10%10.89B | 24.69%8.32B | 25.20%5.51B |
| Operating tax surcharges | 9.30%314.82M | 19.99%222.22M | 19.06%100.81M | 5.11%366.08M | 13.51%288.04M | 17.27%185.21M | 6.57%84.67M | 23.51%348.29M | 17.80%253.77M | 15.20%157.93M |
| Operating expense | 6.10%3.66B | 3.54%2.93B | 8.13%1.49B | 18.77%5.7B | 3.71%3.45B | 31.72%2.83B | 28.04%1.37B | 20.07%4.8B | 17.12%3.33B | 14.77%2.15B |
| Administration expense | 0.32%1.12B | 3.38%822.53M | 3.56%473.35M | 15.43%1.52B | 19.86%1.12B | 28.58%795.64M | 27.54%457.08M | 19.39%1.32B | 10.35%930.89M | 4.82%618.81M |
| Financial expense | 69.86%-182.37M | 48.78%-292.75M | -2,005.68%-123.74M | -89.54%-854.91M | -25.56%-604.99M | -156.10%-571.56M | 23.49%-5.88M | -424.62%-451.04M | -460.38%-481.83M | -418.38%-223.18M |
| -Interest expense (Financial expense) | 61.00%14.2M | 64.67%9.13M | 71.67%4.47M | 21.62%13M | 15.71%8.82M | 15.19%5.55M | 15.15%2.6M | 23.77%10.69M | 21.74%7.62M | 15.30%4.81M |
| -Interest Income (Financial expense) | 17.50%-434.21M | -8.26%-316.36M | -37.07%-189.76M | -129.57%-821.64M | -107.87%-526.34M | -67.48%-292.21M | -56.25%-138.44M | 12.13%-357.91M | 19.44%-253.21M | 21.92%-174.47M |
| Research and development | 3.32%2.59B | -4.11%1.78B | 11.16%947.43M | 17.45%3.43B | 20.19%2.51B | 37.13%1.85B | 21.07%852.3M | 15.78%2.92B | 28.11%2.09B | 27.19%1.35B |
| Credit Impairment Loss | -211.51%-188.2M | -136.21%-134.33M | -40.35%-66.41M | -563.32%-244.19M | -489.62%-60.42M | -749.41%-56.87M | -840.64%-47.32M | -733.20%-36.81M | 63.95%-10.25M | 71.79%-6.7M |
| Asset Impairment Loss | -34.13%-161.03M | -18.59%-91.14M | -2.10%-43.45M | -644.80%-529.51M | -148.73%-120.05M | -169.50%-76.85M | -107.55%-42.56M | 46.03%-71.09M | 27.33%-48.27M | 22.07%-28.52M |
| Other net revenue | 7.34%477.8M | 44.01%440.26M | 152.53%272.94M | -71.40%129.16M | 23.55%445.12M | 43.27%305.72M | 22.19%108.08M | -2.60%451.63M | 12.77%360.29M | 29.79%213.39M |
| Fair value change income | 108.56%126.88M | 280.65%126.28M | --126.03M | 471.42%79.4M | 384.58%60.84M | 255.19%33.18M | ---- | -316.40%-21.38M | -381.92%-21.38M | -216.68%-21.38M |
| Invest income | 1,397.18%64.22M | 3,628.47%63.44M | -183.94%-3.1M | -94.43%-9.84M | -24.47%-4.95M | 30.20%-1.8M | 6.92%-1.09M | -723.73%-5.06M | -90.34%-3.98M | -68.55%-2.58M |
| -Including: Investment income associates | -183.20%-14.23M | -815.04%-14.11M | -183.94%-3.1M | -108.97%-9.82M | -26.32%-5.02M | 40.12%-1.54M | 6.92%-1.09M | -678.93%-4.7M | -90.34%-3.98M | -68.55%-2.58M |
| Asset deal income | 83.62%7.93M | 3,216.14%3.54M | 46.80%-316.18K | -60.02%2.46M | -28.90%4.32M | -114.86%-113.62K | 91.08%-594.32K | 51.61%6.16M | 113.10%6.08M | -51.77%764.43K |
| Other revenue | 11.08%628M | 15.75%472.47M | 30.33%260.19M | 43.29%830.84M | 29.06%565.38M | 50.18%408.18M | 75.13%199.64M | 0.87%579.82M | 4.80%438.08M | 17.44%271.79M |
| Operating profit | 7.99%12.1B | 17.06%8.58B | 23.20%3.57B | 18.92%13.07B | 21.49%11.2B | 22.06%7.33B | 20.74%2.9B | 21.23%10.99B | 21.38%9.22B | 22.00%6.01B |
| Add:Non operating Income | -18.40%29.48M | -14.38%15.56M | -17.63%7.47M | 59.70%56.35M | 29.23%36.13M | 13.48%18.18M | 77.50%9.07M | 51.81%35.28M | 66.84%27.96M | 40.66%16.02M |
| Less:Non operating expense | 48.95%74.23M | 41.34%54.21M | 4.16%22.04M | 59.56%115.28M | 165.45%49.84M | 193.69%38.35M | 2,146.26%21.16M | 0.52%72.25M | -34.17%18.77M | -25.63%13.06M |
| Total profit | 7.72%12.05B | 16.85%8.54B | 23.21%3.56B | 18.78%13.01B | 21.23%11.19B | 21.66%7.31B | 20.03%2.89B | 21.48%10.95B | 21.69%9.23B | 22.21%6.01B |
| Less:Income tax cost | -0.26%1.35B | 11.43%965.61M | 25.59%395.92M | 6.68%1.43B | 20.40%1.35B | 20.70%866.58M | 5.53%315.26M | 32.56%1.34B | 22.26%1.12B | 25.78%717.94M |
| Net profit | 8.82%10.7B | 17.58%7.58B | 22.92%3.16B | 20.47%11.58B | 21.34%9.84B | 21.79%6.44B | 22.09%2.57B | 20.07%9.61B | 21.61%8.11B | 21.74%5.29B |
| Net profit from continuing operation | 8.82%10.7B | 17.58%7.58B | 22.92%3.16B | 20.47%11.58B | 21.34%9.84B | 21.79%6.44B | 22.09%2.57B | 20.07%9.61B | 21.61%8.11B | 21.74%5.29B |
| Less:Minority Profit | 5,267.36%65.57M | 1,144.20%15.2M | 54.87%1.89M | -207.62%-3.81M | -64.60%1.22M | -53.59%1.22M | -35.72%1.22M | 42.15%3.54M | 41.22%3.45M | 145.75%2.63M |
| Net profit of parent company owners | 8.16%10.64B | 17.37%7.56B | 22.90%3.16B | 20.56%11.58B | 21.38%9.83B | 21.83%6.44B | 22.14%2.57B | 20.07%9.61B | 21.60%8.1B | 21.71%5.29B |
| Earning per share | ||||||||||
| Basic earning per share | 8.12%8.7808 | 17.41%6.2446 | 22.80%2.6107 | 20.38%9.5586 | 21.30%8.1216 | 21.76%5.3187 | 22.36%2.126 | 20.55%7.9402 | 22.14%6.6955 | 22.24%4.3682 |
| Diluted earning per share | 8.12%8.7776 | 17.41%6.2413 | 22.80%2.6091 | 20.42%9.5577 | 21.25%8.1185 | 21.69%5.3157 | 22.28%2.1247 | 20.50%7.9369 | 22.14%6.6955 | 22.24%4.3682 |
| Other composite income | -134.90%-69.48M | -141.99%-135.27M | -2,363.48%-116.26M | -9.26%272.83M | 59.46%199.12M | 925.22%322.17M | 106.30%5.14M | 204.70%300.67M | 224.24%124.87M | 212.38%31.42M |
| Other composite income of parent company owners | -136.70%-73.08M | -141.30%-133.06M | -2,240.44%-109.94M | -9.65%271.65M | 59.46%199.12M | 925.22%322.17M | 106.30%5.14M | 204.70%300.67M | 224.24%124.87M | 212.38%31.42M |
| Other composite income of minority owners | --3.59M | ---2.22M | ---6.32M | --1.19M | ---- | ---- | ---- | ---- | ---- | ---- |
| Total composite income | 5.96%10.63B | 9.98%7.44B | 18.16%3.05B | 19.57%11.85B | 21.92%10.03B | 27.13%6.77B | 27.25%2.58B | 28.44%9.91B | 25.38%8.23B | 23.26%5.32B |
| Total composite income of parent company owners | 5.29%10.56B | 9.81%7.43B | 18.39%3.05B | 19.64%11.85B | 21.95%10.03B | 27.17%6.76B | 27.31%2.58B | 28.43%9.91B | 25.37%8.23B | 23.23%5.32B |
| Total composite income of minority owners | 5,561.52%69.17M | 962.61%12.98M | -462.44%-4.43M | -174.16%-2.63M | -64.60%1.22M | -53.59%1.22M | -35.72%1.22M | 42.15%3.54M | 41.22%3.45M | 145.75%2.63M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CN
Overall
Symbol
Price
% Chg
No Data
